Profile data is unavailable for this security.
About the company
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.
- Revenue in USD (TTM)14.79m
- Net income in USD-181.41m
- Incorporated2018
- Employees225.00
- LocationCelularity Inc170 Park AveFLORHAM PARK 07932United StatesUSA
- Phone+1 (908) 768-2170
- Fax+1 (302) 636-5454
- Websitehttps://celularity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lantern Pharma Inc | 0.00 | -17.53m | 65.31m | 21.00 | -- | 1.83 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
CEL-SCI Corp | 0.00 | -29.95m | 65.53m | 43.00 | -- | 4.57 | -- | -- | -0.6304 | -0.6304 | 0.00 | 0.2645 | 0.00 | -- | -- | -- | -87.78 | -70.19 | -103.56 | -78.31 | -- | -- | -- | -15,434.15 | 1.18 | -39.26 | 0.4319 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Avrobio Inc | 0.00 | 30.31m | 66.44m | 13.00 | 2.14 | 0.7477 | 2.17 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Medicinova Inc | 1.00m | -8.41m | 66.70m | 13.00 | -- | 1.11 | -- | 66.70 | -0.1714 | -0.1714 | 0.0204 | 1.22 | 0.0149 | -- | -- | 76,923.08 | -12.55 | -15.36 | -13.06 | -15.90 | -- | -- | -840.85 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
Personalis Inc | 74.15m | -92.61m | 67.52m | 223.00 | -- | 0.5536 | -- | 0.9106 | -1.89 | -1.89 | 1.51 | 2.35 | 0.3172 | 6.50 | 5.04 | 332,493.30 | -39.62 | -28.84 | -46.08 | -34.72 | 25.59 | 28.65 | -124.90 | -96.01 | 3.56 | -- | 0.0209 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Atara Biotherapeutics Inc | 34.70m | -233.11m | 67.54m | 173.00 | -- | -- | -- | 1.95 | -2.12 | -2.12 | 0.3016 | -0.817 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Celularity Inc | 14.79m | -181.41m | 67.74m | 225.00 | -- | 1.99 | -- | 4.58 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
BioXcel Therapeutics Inc | 1.76m | -153.05m | 67.93m | 74.00 | -- | -- | -- | 38.68 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
Intensity Therapeutics Inc | 0.00 | -15.13m | 68.15m | 5.00 | -- | 7.01 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Aileron Therapeutics Inc | 0.00 | -18.07m | 69.09m | 15.00 | -- | 1.20 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Rallybio Corp | 0.00 | -76.28m | 69.22m | 43.00 | -- | 0.7083 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Instil Bio Inc | 0.00 | -123.32m | 69.53m | 49.00 | -- | 0.3378 | -- | -- | -18.96 | -18.96 | 0.00 | 31.65 | 0.00 | -- | -- | 0.00 | -33.63 | -- | -35.47 | -- | -- | -- | -- | -- | -- | -- | 0.2841 | -- | -- | -- | 30.06 | -- | -- | -- |
Checkpoint Therapeutics Inc | 68.00k | -52.32m | 70.02m | 23.00 | -- | -- | -- | 1,029.64 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
vTv Therapeutics Inc | 1.00m | -20.62m | 70.23m | 16.00 | -- | 3.38 | -- | 70.23 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
C.V. Starr & Co., Inc.as of 30 Sep 2023 | 764.07k | 3.51% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 382.60k | 1.76% |
Geode Capital Management LLCas of 31 Mar 2024 | 134.64k | 0.62% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 76.36k | 0.35% |
Cresset Asset Management LLCas of 31 Mar 2024 | 35.00k | 0.16% |
Renaissance Technologies LLCas of 31 Mar 2024 | 29.77k | 0.14% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 27.35k | 0.13% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 24.93k | 0.11% |
HB Wealth Management LLC (GA)as of 31 Mar 2024 | 24.00k | 0.11% |
City National Rochdale LLCas of 31 Mar 2024 | 22.50k | 0.10% |